GSK plc GSK announced that the European Medicines Agency (EMA) has accepted the regulatory application seeking approval to ...

The Food and Drug Administration (FDA) expanded the approval of Moderna’s RSV vaccine late Thursday to include people 18 to ...

For the 2025-2026 respiratory viral season, Moderna intends to have mResvia available for both FDA-approved patient populations.

The incidence of RSV across 5 respiratory virus seasons was substantial among adult patients with high-risk underlying conditions.

Expanded indication builds on existing U.S. FDA approval of mRESVIA for adults aged 60 and older CAMBRIDGE, MA / ACCESS ...

What is Abrysvo used for? Abrysvo (respiratory syncytial virus vaccine) is commonly given to help prevent lower respiratory tract disease (such as pneumonia or bronchiolitis) caused by ...

Respiratory Syncytial Virus or RSV is one of the most common respiratory viruses circulating today. Often thought of as only being dangerous to babies and toddlers due to how often child-related ...

Respiratory syncytial virus (RSV) is a common viral infection that may lead to serious complications in certain groups. Since 2023, vaccines are now available and are highly recommended ...

So, which respiratory virus invaded your cells? Several types of viruses could be the culprit: respiratory syncytial virus (RSV), influenza, parainfluenza viruses, metapneumovirus, rhinoviruses ...

Dublin, Nov. 21, 2024 (GLOBE NEWSWIRE) -- The "Respiratory Syncytial Virus (RSV) - Pipeline Insight, 2024" clinical trials has been added to ResearchAndMarkets.com's offering. "Respiratory ...

enterovirus and respiratory syncytial virus. Although the information is recorded weekly, the data doesn’t reflect the exact number of cases across the state, according to department ...

Respiratory syncytial virus (RSV) is a common virus that affects the throat, nose, and lungs. Symptoms include a runny nose, congestion, sneezing, wheezing, cough, and fever, and these are often ...